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Seminars in Naccumulation within the glomerulus, and pathogenetically by aberrant regulation of the alternative pathway of
complement. Dense deposit disease is distinguished from other forms of C3 glomerulopathy by its
characteristic appearance on electron microscopy. The extent to which dense deposit disease also differs
from other forms of C3 glomerulopathy in terms of clinical features, natural history, and outcomes of treatment
including renal transplantation is less clear. We discuss the pathophysiology of C3 glomerulopathy, with
evidence for alternative pathway dysregulation obtained from affected individuals and complement factor H
(Cfh)-deficient animal models. Recent linkage studies in familial C3 glomerulopathy have shown genomic
rearrangements in the Cfh-related genes, for which the novel pathophysiologic concept of Cfh deregulation
has been proposed.
Semin Nephrol 33:493-507 C 2013 Elsevier Inc. All rights reserved.
Keywords: C3 glomerulopathy, dense deposit, complementIn 1962 the renal pathologist, Berger, and electronmicroscopist, Galle, published the ﬁrst descriptionof dense deposit disease (DDD), based on needle
biopsies performed in three patients at the Necker
Hospital in Paris.1 They later extended their observa-
tions to a total of 14 patients.2 DDD is a rare lesion, so
named because of the appearance on electron micro-
scopy (EM) of extremely dark, ribbon-like, electron-
dense material in the central layer (lamina densa) of the
glomerular basement membrane (GBM). Deposits also
may occur in the mesangium, Bowman’s capsule, and
tubular basement membrane. DDD has variable mor-
phology on light microscopy (LM), with a mesangio-
proliferative3 or membranoproliferative4,5 appearance
being most common. Other patterns including endo-
capillary proliferative and crescentic are described in
both native disease and post-transplant recurrence.6
DDD is therefore a more accurate name for this lesion
than membranoproliferative glomerulonephritis (MPGN)
type 2.7 Immunoﬂuorescence (IF) or immunohisto-
chemistry (IHC) typically shows intense glomerularsee front matter
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ephrology, Vol 33, No 6, November 2013, pp 493–507C3 staining with little or no immunoglobulin (Ig).8
However, this appearance is not speciﬁc for DDD, with
one early French series of 49 patients with MPGN
comprising 15 patients with isolated or predominant
glomerular C3 staining, of whom only 5 patients had
intramembranous dense deposits characteristic of
DDD.9 In a 2007 French series of 19 patients, Servais
et al10 introduced the term C3 glomerulonephritis
(C3GN) to describe isolated glomerular C3 without
intramembranous deposits. Accordingly, the term C3
glomerulopathy was proposed11 for all glomerular
lesions, including DDD, that are characterized by
predominant C3 accumulation within the glomerulus
using IF/IHC. The presence of predominant or isolated
C3 accumulation suggests activation of the alternative
pathway (AP) of complement, and many cases of
C3 glomerulopathy show genetic or acquired AP
dysregulation.
Recognizable entities within C3 glomerulopathy
include those with characteristic morphologic appear-
ances (DDD and electron-dense intramembranous
GBM transformation) and those with clear etiology
(complement factor H-related 5 [CFHR5] nephropathy
and the presence of an abnormal CFHR5 protein).
Because postinfectious GN typically is characterized
by a reversible decrease in serum C3 and the presence
of glomerular C3 without Ig, differentiation from C3
glomerulopathy sometimes may be possible only with
knowledge of the clinical course. In a number of cases
in which there has been persistent renal disease after
diagnosis of postinfectious GN, AP abnormalities have
been detected and subsequent biopsy specimens were
consistent with C3 glomerulopathy.12–15 This includes
a report of a young girl with acute post-streptococcal
GN and low serum C3 levels in whom recurrent
macroscopic hematuria prompted biopsy examinations
9 and 20 months after the initial presentation.12 The
biopsy specimens showed MPGN, with IHC showing
capillary wall and mesangial C3 without Ig or C1q, and493
T.D. Barbour et al.494EM showing intramembranous and mesangial deposits.
A heterozygous sequence variant in the CFHR5 gene,
in which duplication of a single nucleotide resulted in a
premature stop codon, later was identiﬁed in the girl
and her unaffected mother. Notwithstanding some
common pathogenetic associations, atypical hemolytic
uremic syndrome (aHUS) is not considered a C3
glomerulopathy because endothelial injury usually is
seen without signiﬁcant C3 deposition or electron-
dense deposits.16
HISTOLOGIC FEATURES
Electron-dense deposits are seen within the glomerulus
in all forms of C3 glomerulopathy. DDD is deﬁned by
the intramembranous location of these deposits, their
intensely osmiophilic appearance forming ribbons, and
the associated transformation of the GBM (Fig. 1).
Conﬁrmation of DDD requires EM, although the
diagnosis can be suspected with a high degree of
conﬁdence if the typical LM and IF/IHC features are
present. The distinction between DDD and C3GN is
sometimes difﬁcult even using EM,17–19 with debates
about the extent of intramembranous deposits required
for EM diagnosis of DDD.20 Furthermore, because the
ribbons of DDD typically are discontinuous and mayA
C
Figure 1. Renal histology in individuals with DDD. (A) Lig
proliferative pattern with double contours of the GBM. (B)
with immunoperoxidase showing strong capillary wall
(D) Characteristic sausage-like, intramembranous, osmiop
permission from Dr. C. Nast.be more prominent in some capillary loops than others,
they may be missed as a result of biopsy sampling
error, leading to a diagnosis of C3GN. Such discrep-
ancies may be important in the context of prognostic or
therapeutic studies comparing outcomes in DDD
and C3GN.
The ultrastructural characteristics of C3GN are less
clearly deﬁned, other than by the absence of the
hallmarks of DDD (Fig. 2). In the original French
C3GN series by Servais et al,10 two main histologic
groups were described. The ﬁrst group had typical
features of MPGN type 1, with mesangial proliferation,
double contours, and subendothelial, mesangial, and
(less commonly) subepithelial deposits. The second
group lacked mesangial proliferation, a membranopro-
liferative pattern, or subendothelial deposits. EM was
performed in only two patients (conﬁrming the absence
of dense intramembranous deposits).10 This series
recently was updated to provide data on 29 DDD
patients, 56 C3GN patients, and 49 MPGN type
1 patients (both adults and children).21 Occasionally,
the EM appearance of C3GN closely resembles that
previously described as a subtype of MPGN type 3 by
Strife et al.22 In CFHR5 nephropathy, histologic
appearances (Fig. 2E and F) include mesangial and/or
capillary wall C3 deposits on IF; a normal or mesan-B
D
ht microscopy with silver stain showing a membrano-
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Figure 2. Renal histology in individuals with C3GN. (A) Light microscopy showing a membranoproliferative
pattern with segmental endocapillary neutrophil infiltration. (B) Electron microscopy showing moderately dense
capillary wall and mesangial deposits. (C) Light microscopy showing mesangial expansion and
(D) immunoperoxidase showing mesangial C3 in the same individual. (E) Immunoperoxidase showing granular
capillary wall C3, in this case without conspicuous mesangial deposits, and (F) electron microscopy showing
predominantly subendothelial deposits (and a transmembranous deposit) in an individual with CFHR5
nephropathy.
DDD and C3 glomerulopathy 495gioproliferative pattern on LM; and mesangial, sub-
endothelial, and occasional subepithelial deposits of
only moderate density on EM. Subepithelial deposits
may in fact be present in all types of C3 glomerulop-
athy, sometimes with so-called humps identical to
those characteristically seen in postinfectious GN. In
one DDD series, paramesangial subepithelial deposits
correlated with low serum C3 owing to C3 nephritic
factor (C3NeF) activity23 and were composed of
C3c.24 Laser microdissection and mass spectrometry
of glomerular tissue has shown a similar proteomicproﬁle for DDD25 and C3GN17 that includes alterna-
tive and terminal pathway complement components.
CLINICAL FEATURES
DDD has an estimated prevalence of 2 to 3 per million
population26 and traditionally is viewed as a diagnosis
of childhood and young adulthood.27 Several series
have shown a signiﬁcantly younger mean age at
diagnosis among DDD patients compared with MPGN
types 1/328–30 or C3GN.21 However, some DDD
T.D. Barbour et al.496cohorts have comprised numerous older patients,31
including one recent US series of 18 adults and 14
children in which 39% of adults were older than age
60 at diagnosis.4 Although this study and several
others30,32–34 found that DDD was almost twice as
common in females as males, some have found the
opposite,35,36 whilst the majority of studies have found
no differences between males and females with
DDD3,5,21,27,37–41 or C3GN.21,42 Native renal manifes-
tations of C3 glomerulopathy are diverse and non-
speciﬁc, with hypertension, hematuria, proteinuria
(with or without nephrotic syndrome), and renal failure
all reported. Most studies have found no difference in
presenting features between DDD and MPGN type
1.28,29,32,38,40 However, nephrotic syndrome was
approximately twice as common in MPGN type 1 as
either DDD or C3GN in the recently updated French
C3 glomerulopathy series.21
In CFHR5 nephropathy, persistent microscopic
hematuria with or without episodes of synpharyngitic
macroscopic hematuria (clinically identical to those
seen in IgA nephropathy43) is the usual presentation.
Identical features occasionally have been reported in
DDD patients,34,44 in whom the clinical and histologic
overlap with acute postinfectious GN suggests that
intercurrent infection is important in renal injury when
AP dysregulation is present. Thus, symptoms of
respiratory tract infection preceding renal symptoms
have been described in children (not usually adults)
with DDD,4,5,17,35,38–41,45,46 sometimes in association
with increased anti–streptolysin O titers.17,38,41,46
Nonrenal manifestations of DDD include ocular
drusen, acquired partial lipodystrophy (PLD), type
1 diabetes mellitus, and monoclonal gammopathy of
undetermined signiﬁcance (MGUS). Ocular drusen
are lipoproteinaceous deposits of complement-
containing debris between the basal surface of the
retinal pigment endothelium and Bruch’s membrane.
The clinical association of ocular drusen with DDD
was ﬁrst reported in 1989,47 and appears to be related
to structural and functional similarities between
Bruch’s membrane, a multilaminar extracellular
matrix that separates the retina from the blood vessels
in the choroid, and the GBM. Ocular drusen are also
a manifestation of age-related macular degeneration
(AMD),48 the leading cause of blindness in the
industrialized world, for which a number of shared
genetic risk factors with DDD are discussed later.
However, unlike AMD, drusen in patients with DDD
are said to occur at a young age and to be associated
with only a modest risk of progressive visual loss.49
In the recent therapeutic trial of eculizumab in DDD
and C3GN, among several patients identiﬁed as
having ocular drusen, one patient had C3GN.50
PLD involves loss of subcutaneous fat from the face
and upper body. An association with GN was ﬁrstnoted in 1958.51 Early reports of PLD in patients with
DDD52 and C3NeF-associated MPGN (without EM)53
were followed by several MPGN cohorts in which
PLD was associated speciﬁcally with DDD.29,31,38 In
the updated French C3 glomerulopathy series, PLD
was noted only in the DDD group,21 affecting 17% of
DDD patients (versus o5% in other recent DDD
cohorts26,54). However, in an early PLD series com-
prising six patients with MPGN (all having C3NeF and
low serum C3 levels), one patient had only subendo-
thelial deposits on EM.55 Moreover, the Necker hos-
pital group reported two patients with PLD and MPGN
in whom IF was positive for both C3 and IgG.56 In
a 2004 literature review of PLD, MPGN was the most
common associated renal lesion, but only slightly more
than half of MPGN cases were shown to be DDD, with
MPGN types 1/3 also represented.57 In the majority of
cases of PLD, including those associated with low
serum C3 levels, renal disease was not found.57 A
signiﬁcantly increased risk of diabetes mellitus type
1 was reported in patients and families with DDD in
a US questionnaire-based study of 98 patients
(although ascertainment bias cannot be excluded).39 It
has been suggested that MGUS is associated with
DDD4,58,59 and C3GN,18,60 and that it may confer a
poor renal prognosis.
PROGNOSIS
Progression to end-stage kidney disease (ESKD),
despite treatment, is said to occur in approximately
half of patients with a diagnosis of DDD of 10 or more
years.31,34,49,61,62 In the recently updated French C3
glomerulopathy series, overall 10-year progression to
ESKD was 36.5% (with a mean follow-up period of 11
years).21 No signiﬁcant difference was seen between
the three diagnostic categories (DDD, C3GN, and
MPGN type 1). This is consistent with the ﬁnding in
earlier MPGN cohort studies that DDD was not more
likely than other forms of MPGN to progress to
ESKD.7,29,31,40,63–65 Other series found that an appa-
rent increase in ESKD rates probably was confounded
by a higher incidence of crescents30,38 or reduced
GFR61 at diagnosis in the DDD versus non-DDD
patient groups.
The impact of clinical or histologic variables on
outcomes of C3 glomerulopathy has been assessed in
numerous retrospective cohort studies. In the two most
recent DDD cohorts, reduced GFR at diagnosis was
associated signiﬁcantly on multivariate analysis with
progression to ESKD.4,21 In CFHR5 nephropathy, in
which progressive disease is characterized by hyper-
tension, proteinuria, and chronic renal failure, ESKD
has been reported in 18 of 91 carriers (or 20%) of the
heterozygous CFHR5 gene mutation. Of these, 14 were
men and 4 were women, a difference that remains
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consistently to correlate with disease outcomes in
DDD or other forms of C3 glomerulopathy. This is
partly because of the limited number of end points that
can be assessed in mostly small cohorts. In the updated
French C3 glomerulopathy cohort,21 adults with DDD
had signiﬁcantly reduced renal survival compared with
children with DDD, adults with C3GN, and adults with
MPGN type 1. However, the DDD adult subgroup
comprised only 11 patients, and because other differ-
ences between these subgroups were not assessed it is
difﬁcult to determine if this was a robust conclusion.
For some variables, including the presence of crescents
on the diagnostic biopsy specimen (found to predict a
rapid progression to ESKD in some DDD cohorts38,66
but not others4,29,35), it now seems especially clear
that prognostic value cannot be assessed adequately
through retrospective cohort analyses. This is exempli-
ﬁed by the US DDD cohort study in which it was
suggested that the reason crescents did not correlate
with outcomes may have been the increased use of
immunosuppressants in such patients.4PATHOGENESIS
C3 Nephritic Factors
Reduced serum C3 (but not C4) is consistent with AP
dysregulation, but is neither sensitive nor speciﬁc for
the diagnosis of DDD/C3GN. In recent cohort studies,
isolated low C3 level was found in only a proportion
of patients with DDD4,21 and C3GN.21,42 C3NeF, ﬁrst
described in a patient with “persistent hypocomple-
mentemic glomerulonephritis,”67 is an autoantibody
that binds to a neoepitope on C3bBb, the C3 con-
vertase of the AP, stabilizing it against complement
factor H (Cfh)-mediated decay and prolonging its
C3-cleaving action.68 A second type of C3NeF was
found to display slower C3 and C5 activation69 and
dependence on properdin for convertase stabiliza-
tion.70 It has been reported in very small series that
properdin-dependent C3NeFs are more characteristic
of MPGN types 170,71 and 3,70 whereas properdin-
independent C3NeFs are found more often in DDD
and PLD.71
In the updated French C3 glomerulopathy cohort,21
C3NeFs were signiﬁcantly more common in patients
with DDD than C3GN or MPGN type 1 (consistent
with earlier studies29,31,72). Patients with C3NeFs also
had generally lower C3 levels (although C3 was
normal in 40% of patients with C3NeF). Here, as
in most DDD/C3GN studies, serum C3 levels and the
presence of C3NeF did not correlate with disease
outcomes. The identiﬁcation of C3NeFs in patients
with other forms of GN and in healthy individuals
(discussed in one recent study73) underlines a lack ofspeciﬁcity. In CFHR5 nephropathy, C3 levels typically
are normal and C3NeF is absent.74
Autoantibodies that bind to native factor B (Cfb)
and stabilize the AP C3 convertase75 or target both Cfb
and C3b76 also have been described in patients with
DDD. An early report showed that circulating mono-
clonal Ig λ light chain dimers were able to activate the
AP.77 The λ light chain dimers were found to bind
short consensus repeat (SCR) 3 on the Cfh molecule,
blocking one of its C3b interaction sites.78 Subse-
quently, anti-Cfh autoantibodies have been identiﬁed
in patients with DDD59,73,79 and C3GN.17,18Family Studies
Renal biopsy data for a number of family studies in C3
glomerulopathy are shown in Table 1. These studies
indicate a genetic basis for a small number of C3
glomerulopathy cases, although the genetic defect has
been characterized and an underlying pathogenic
mechanism proposed in only a handful of families.
These include cases associated with homozygous Cfh
deﬁciency or homozygous loss-of-function Cfh muta-
tion, heterozygous gain-of-function C3 mutation, and
CFHR mutations leading to enhanced Cfh deregulation
(summarized later and in Figure 3). Two Algerian
brothers of consanguineous parents were reported with
severe Cfh deﬁciency and autosomal-recessive “atyp-
ical DDD” as shown on EM by discontinuous intra-
membranous deposits.44 Renal disease presented
during infancy with intermittent macroscopic hematu-
ria and infections (including pharyngitis) together with
failure to thrive and developmental delay in the
younger sibling. Both brothers were negative for
C3NeF but had very low serum levels of C3, Cfb,
properdin, and C5 with normal classic pathway com-
ponents. A homozygous missense mutation in SCR
7 of the Cfh gene, causing a substitution of a cysteine
with a serine residue, subsequently was identiﬁed in
the elder brother.80 Both parents and two other children
without renal disease had half-normal Cfh levels,
consistent with heterozygosity. A young girl presenting
with recurrent macroscopic hematuria and undetectable
serum C3, Cfb, and Cfh was found to have C3GN with
a mesangioproliferative pattern and predominant
mesangial deposits on EM.81 A homozygous missense
mutation was detected on SCR 16 of Cfh that resulted
in a cysteine to serine change. Both unaffected parents
were heterozygous for the Cfh mutation and displayed
low-normal Cfh levels, while an unaffected sister had
two normal Cfh alleles and high-normal Cfh levels.
Intriguingly, an earlier report concerned a patient with
severe Cfh deﬁciency in association with type 3 colla-
gen glomerulopathy82 (more likely representing
chronic thrombotic microangiopathy16) in whom a
different homozygous missense mutation was
Table 1. Renal Biopsy Data in Family Studies of C3 Glomerulopathy
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Figure 3. Disease mechanisms in C3 glomerulopathy, based on
genetic defects identified in family studies. (A) Physiological reg-
ulation of C3 activation to C3b via the alternative pathway is
mediated by Cfh. Competitive inhibition of Cfh by CFHR pro-
teins is termed Cfh deregulation. (B) Homozygous deficiency
or dysfunction of Cfh results in excessive C3 activation.
(C) Hyperfunctional C3 produces excessive C3 activation despite
normal Cfh activity. (D) Abnormal CFHR proteins enhance Cfh
deregulation, leading to excessive C3 activation.
DDD and C3 glomerulopathy 499identiﬁed at the same site on SCR 16.83 The substitu-
tion of a cysteine residue (in this case with a tyrosine)
altered the secondary structure of the Cfh protein,
resulting in its nonsecretion.84 A young girl was
reported with macroscopic hematuria, very low C3
and Cfh levels, and endocapillary GN with predom-
inant glomerular C3.85 A homozygous missense muta-
tion on SCR 2, causing an exchange of proline to
serine, was apparently the result of paternal isodisomy.
The patient also was homozygous for a risk haplotype
for the membrane cofactor protein (MCP) gene (dis-
cussed later).86
Two young daughters of consanguineous Turkish
parents had C3GN with low C3, positive C3NeF, and
only slightly reduced serum Cfh levels.87,88 A loss-of-
function homozygous mutation in Cfh involving dele-
tion of a single codon in SCR 4 was found to produce a
circulating mutant Cfh protein with impaired binding
to C3b, defective decay accelerating activity, and
reduced factor I (Cﬁ) cofactor activity. Both patients
also were homozygous for the DDD/AMD-associated
Y402H Cfh polymorphism (discussed later). A mother
and her twin adult sons had DDD in association with
half-normal C3 and Cfb levels and normal Cfh
levels.89 A gain-of-function heterozygous mutation of
the C3 gene involving deletion of two codons was
found to produce a hyperfunctional C3 protein. Mutant
C3 was unable to be activated by the C3 convertase of
the AP. However, after its conversion by proteases to
C3b or by spontaneous hydrolysis of the internal
thioester (C3 tickover) to C3(H2O), it formed a C3
convertase that was resistant to regulation by Cfh. This
resulted in accelerated breakdown of wild-type C3 thatappeared to be restricted to the ﬂuid phase, because
regulation in vitro by decay accelerating factor (DAF, a
surface-expressed complement regulatory protein) was
intact. Similarly, mutant C3b and C3(H2O) did not
undergo Cﬁ-mediated proteolysis in the ﬂuid phase
(being dependent on Cfh cofactor activity), whereas
proteolysis proceeded efﬁciently in the presence
of MCP.
In CFHR5 nephropathy, multiplex-ligation probe
ampliﬁcation enabled the identiﬁcation of a novel
heterozygous mutation in the CFHR5 gene involving
internal duplication of the initial two N-terminal SCRs
in two affected families originally from the Troodos
region of Cyprus.74 The ﬁnding of a common mutation
in these families suggested a founder effect, and
subsequently diagnostic polymerase chain reaction
enabled the identiﬁcation of numerous additional
affected individuals and families from all over Cyprus
(some with a previous diagnosis of MPGN type 1). A
total of 91 carriers of the same heterozygous founder
mutation from 16 apparently unrelated Greek-Cypriot
families was later reported, with a disease penetrance
of 90%.90 An Irish family was ﬁrst reported with
autosomal-dominant MPGN type 391 (now reclassiﬁed
as C3 glomerulopathy) and linkage to the regulators of
complement activation locus.92 A novel hybrid
CFHR3-1 gene now has been identiﬁed encoding an
abnormal CFHR3-1 protein in affected family
members.93Cfh Deregulation
Until recently, the biological role of the ﬁve CFHR
proteins has been unclear, although the presence of
polymorphisms involving homozygous deletion of
CFHR genes (most commonly ΔCFHR3/1)102 in
healthy populations suggested that the CFHR3 and
CFHR1 proteins were nonessential. Recently, CFHR1,
CFHR2, and CFHR5 have been shown to possess a
common dimerization motif located within the highly
conserved ﬁrst two N-terminal SCRs of these particular
CFHR proteins. It is now believed that, unlike Cfh,
these CFHR proteins do not have any complement
inhibiting actions in vivo. Rather, they compete with
Cfh for binding to C3b, thereby enhancing C3 activa-
tion in a process termed Cfh deregulation.103 Both
dimerization and deregulation have implications for
understanding how CFHR proteins mediate autosomal-
dominant C3 glomerulopathy. In CFHR5 nephropathy,
the mutation results in the duplication of the dimeriza-
tion motif and enables generation of large complexes
that have enhanced deregulation.103 Enhanced dereg-
ulation also has been shown using serum containing
the abnormal (hybrid) CFHR3-1 protein.103 The cur-
rent paradigm is that there is either continuous or
intermittent (eg, during infection) activation of C3
T.D. Barbour et al.500along the GBM that is controlled by Cfh. In the
presence of abnormal CFHR proteins, enhanced dereg-
ulation of Cfh enables C3 to accumulate along the
GBM. This paradigm would predict that a lack of
CFHR proteins (eg, through the common ΔCFHR3/1
allele) would enhance Cfh action and become a
protective factor in C3 glomerulopathy or complement-
mediated disease in general. It also may explain the
protective effect of ΔCFHR3/1 in AMD102,104 and IgA
nephropathy.105 Homozygous ΔCFHR3/1 was absent in
one cohort of 68 DDD patients, despite a rate among
healthy control subjects of 3%.26Other Genetic Associations
Additional genetic variations in complement proteins
and/or regulators have been identiﬁed using a candi-
date gene approach in individuals and cohorts with C3
glomerulopathy. Most of those in whom a rare genetic
variant has been found have a family history of disease
(and hence a higher pretest probability of genetically
determined susceptibility). The relatively poor yield of
genetic screening to date in nonfamilial cases is
exempliﬁed by the French C3 glomerulopathy cohort,
in which mutations in one of three genes (Cfh, Cﬁ, and
MCP) was reported in only 18% of all patients
screened.21 Cfh mutations were the most common,
occurring in 9 of 16 individuals with a family history,
but in only 8 nonfamilial cases. Another remarkable
ﬁnding in this study was of no overall difference in the
proportion of patients with DDD, C3GN, and MPGN
type 1 in whom mutations affecting complement
regulatory proteins were found. Thus, patients with
homozygous Cfh mutations were identiﬁed in DDD (as
outlined earlier), C3GN (patient 3106), and MPGN type
1 (patient 2106 and case 1107). However, the bulk of
mutations identiﬁed in the French cohort were hetero-
zygous. Two patients treated with eculizumab in the
recent therapeutic trial also had heterozygous muta-
tions affecting Cfh and MCP.50 Unlike homozygous
Cfh deﬁciency, for which an animal model exists
(discussed later), the functional basis of heterozygous
mutations in C3 glomerulopathy remains unclear,
notwithstanding that some have shown a correlation
with AP dysregulation in patients with aHUS. Of note,
homozygous Cﬁ deﬁciency, ﬁrst reported in a patient
with extremely low C3 and increased susceptibility to
infection,108 has not been reported in association with
C3 glomerulopathy.
Screening of patient cohorts, followed by compar-
ison with control populations, also identiﬁed common
allelic variants that may modify risk of C3 glomerul-
opathy. Multiple genetic variants potentially conferring
either increased risk or protection for C3 glomerulop-
athy and/or other complement-related phenotypes are
said to deﬁne an individual’s complotype. Thus,single-nucleotide polymorphisms (SNPs) in the Cfh
and C3 genes and a deletional copy number variation
in C4A are associated with increased risk of DDD,
whereas an SNP in CFHR5 is protective.109 An SNP in
MCP also is associated with an increased risk of C3GN
and MPGN type 1.21 At-risk haplotypes combin-
ing multiple SNPs in Cfh110 and C3109 have been de-
lineated for DDD, together with a protective Cfh
haplotype.110 An at-risk MCP haplotype for C3GN
and MPGN type 1 and a protective MCP haplotype for
DDD and C3GN also have been reported.21 In some,
but not all, cases, functional studies showing AP
dysregulation have provided evidence in support of
the genetic association.111
In AMD, approximately 50% of the population-
attributable risk is accounted for by common poly-
morphisms in the Cfh gene. Several AMD-associated
Cfh sequence variants have been shown to confer a
common susceptibility to DDD.112 One important exa-
mple is the Y402H substitution of a histidine (H) for a
tyrosine (Y) residue on SCR 7, strongly associated with
both AMD110,112 and DDD110 in Caucasian but not
Asian populations. Functional studies have indicated
that Y402H affects differential binding of Cfh to glyco-
saminoglycans within Bruch’s membrane and the
glomerulus.113 An illustrative case relates to a 56-
year-old man in whom ESKD developed as a result
of DDD (without diagnostic EM), followed by new-
onset AMD, causing eventual blindness.114 In this
individual, genetic susceptibility to AMD and DDD
derived from a heterozygous Cfh mutation in SCR 7, a
homozygous risk haplotype comprising the H402
variant for SCR 7, and several other AMD risk factors.Animal Models
Pigs115 and mice116–120 with homozygous Cfh deﬁ-
ciency have provided an important experimental model
of DDD. In Norwegian Yorkshire piglets (now
extinct), a lethal Cfh mutation occurred spontaneously
and was associated with severe renal disease described
as porcine MPGN type 2. Gene-targeted Cfh-deﬁcient
mice show AP dysregulation with extremely low
plasma C3 levels.116 Cfh/ mice develop albuminu-
ria and MPGN, with signiﬁcantly reduced survival
compared with wild-type mice. In both models glo-
merular C3 without Ig is seen at an early stage and
precedes the appearance on EM of capillary wall dense
deposits. These electron-dense deposits are initially
subendothelial rather than intramembranous, and show
positive staining for C3 using immunoelectron micro-
scopy. The absence of extraglomerular C3 is reminis-
cent of “atypical DDD,” as described in the family
study of homozygous Cfh deﬁciency.44 Cfh/ mice
crossed with Cfb-deﬁcient mice do not show low
plasma C3 levels or glomerular changes, indicating
DDD and C3 glomerulopathy 501that uncontrolled C3 activation via the AP is critical to
renal pathogenesis. Injection into Cfh/ mice of a
single dose of puriﬁed murine119 or human120 Cfh
restores plasma C3 levels to normal at 24 hours,
accompanied by the resolution on IF of GBM C3
staining and the appearance of mesangial C3. In
affected piglets, weekly plasma infusions containing
Cfh also reduced the severity of GN and improved
survival.121
The role of C5 in this phenotype was studied by
crossing Cfh/ mice with those lacking C5.117
Although spontaneous MPGN with capillary wall
deposits was still observed, glomerular cellularity/
crescents were reduced with improved renal function
and reduced mortality. Cfh/ mice with accompany-
ing C5 deﬁciency also were less susceptible to renal
injury induced by sheep nephrotoxic serum, whereas
Cfh/ mice with or without accompanying C6
deﬁciency showed an inﬂux of neutrophils into the
glomerulus. This suggests that the production of C5a
rather than membrane attack complex (MAC) forma-
tion mediated renal damage. Cfh/ mice injected
with anti-C5 antibodies before administration of neph-
rotoxic serum also were protected, suggesting that anti-
C5 therapy may be beneﬁcial in human beings with C3
glomerulopathy owing to Cfh deﬁciency (eg, during
disease ﬂares). In mice with homozygous deﬁciency of
Cﬁ, an inability to metabolize C3b results in uncon-
trolled AP activation and low circulating C3 levels. In
Cﬁ/ mice only C3b is evident in plasma, consistent
with the C3 proﬁle in human beings with total Cﬁ
deﬁciency.122 Cﬁ/ mice show mesangial C3 accu-
mulation and nodular mesangial expansion, but with-
out GBM C3 staining or features of MPGN.
Unexpectedly, in mice with combined homozygous
deﬁciency of Cfh and Cﬁ, both the plasma C3 proﬁle
and glomerular C3 pattern are identical to those seen in
Cﬁ deﬁciency alone.118 Injection into Cfh/.Cﬁ/
mice of a source of murine Cﬁ resulted in cleavage of
C3b, generating fragments including iC3b. This was
accompanied by loss of mesangial C3 staining, and the
appearance of GBM C3 staining. It therefore appears
that cleavage of C3b was critical for GBM C3 staining
to occur, and that measures to prevent conversion of
C3b to iC3b might be useful therapeutically in patients
in whom GBM C3 accumulation is shown.
Recently, an additional aspect of renal pathogenesis
was elucidated through the generation of mice with
Cfh and properdin deﬁciency.123,124 Because properdin
prolongs the cleaving activity of the AP C3 convertase,
it was hypothesized that genetic deﬁciency of proper-
din (as a positive regulator of the AP) would amelio-
rate the renal phenotype of Cfh deﬁciency.
Unexpectedly, Cfh/.P/ mice showed more
severe MPGN and more intense GBM C3 staining
than Cfh/ mice.123 Plasma C3 levels did not differbetween Cfh/.P/ and Cfh/ mice, although
only Cfh/.P/ mice showed (fractional amounts
of) intact C3. Plasma C5 was absent in Cfh/ mice
(consistent with previous data125), but was detected at
low levels in Cfh/.P/ mice. One explanation for
these observations is that higher levels of intact C3 in
Cfh/.P/ mice may increase the availability of
iC3b in the circulation for accumulation along the
GBM, whereas the increased availability of C5 also
may contribute to the more severe glomerular inﬂam-
mation seen in these mice. Although the predominant
C3 depletion seen in Cfh/.P/ mice closely
resembles the C3 proﬁle in human subjects with
properdin-independent C3NeFs, the pattern of C3 and
C5 depletion in Cfh/ mice is analogous to
properdin-dependent C3NeFs.
TREATMENT
No treatment has been proven to be beneﬁcial in C3
glomerulopathy.
Antihypertensive/antiproteinuric therapy, particu-
larly via renin-angiotensin-aldosterone system (RAAS)
blockade with angiotensin-converting enzyme inhibi-
tors or angiotensin-receptor blockers, generally is
recommended in GN.126 Evidence in support of RAAS
blockade in C3 glomerulopathy speciﬁcally is limited
to retrospective cohort studies (which are subject to
treatment bias). In the French C3 glomerulopathy
cohort, RAAS blockade, but not use of immunosup-
pressants, was associated with a signiﬁcant increase in
renal survival,21 whereas in the US DDD cohort a
nonsigniﬁcant reduction in progression to ESKD was
found with combined RAAS blockade and steroids.4
After early reports of children with DDD in whom
alternate-day steroids were associated with histologic
regression,127 a 1992 randomized controlled trial
showed clinical beneﬁt in 70 children with MPGN,
of whom 14 had DDD (without a subgroup analy-
sis).128 In the absence of subsequent randomized
controlled trials, reports purportedly showing response
to steroids in DDD are complicated by the highly
variable natural history, which includes rare occur-
rences of sustained clinical remission even without
treatment.129,130 Thus, in one pediatric series of likely
C3 glomerulopathy, treatment with steroids, initiated
on the basis of biopsy evidence of acute glomerular
inﬂammation including crescents, led to clinical
improvement in a number of cases.131 However, an
identical improvement was seen in an untreated patient.
Use of steroids and immunosuppressants may appear
most justiﬁed in patients with C3 glomerulopathy who
develop rapidly progressive GN (because this would
prompt their use for other causes of GN). However,
post-transplant recurrence of C3 glomerulopathy
(including with crescents on biopsy, discussed later)
T.D. Barbour et al.502and aHUS132 suggests that immunosuppression (as
used in the transplant period) may be ineffective for
AP-mediated renal disease. The iatrogenic risk of
infection, potentially triggering complement activation
and exacerbation of nephritis, also must be weighed.
Treatment with the anti-CD20 monoclonal antibody
rituximab has been reported with success in a single
case of DDD related to anti-Cfb/C3b autoantibodies.76
Immunosuppressive treatment for underlying hemato-
logic malignancies including MGUS, in patients with
associated C3 glomerulopathy, leading to improvement
in renal parameters in some reports60 but not others,18
is not discussed here.
Restoration of normal AP regulation is a major goal
of current research into treatment of C3 glomerulop-
athy. The animal models suggest that puriﬁed or
recombinant Cfh replacement might be beneﬁcial in
Cfh-deﬁcient patients. Although this therapy is not
currently available, long-term plasma infusion was
effective and well tolerated in the sisters with familial
C3GN related to circulating mutant Cfh.87 Elsewhere
plasma infusion/exchange has been reported with only
mixed success, including in the setting of recurrent
post-transplant DDD.133 A therapeutic role for anti-C5/
C5a therapy in C3 glomerulopathy ﬂares is suggested
by experimental data in animal models and by the
observation in DDD patients with rapidly progressive
GN that the glomerular deposits contain C5.23 The C5-
inhibitor eculizumab has been reported with success in
several cases of DDD134,135 (including a patient with
post-transplant recurrence associated with renal fail-
ure136) and one of MPGN type 1.137 However, it also
has been reported with failure in another DDD
patient,134 and with mixed results in a recent prospec-
tive, uncontrolled trial in 6 adults with native or
recurrent post-transplant DDD or C3GN.50 At the
conclusion of a 1-year course of eculizumab, a clinical
improvement was observed in three of the trial patients
(two showing reduced inﬂammation on biopsy138). In
the future, agents that either inhibit the C3 convertase
of the AP or remove C3 (and/or C3 fragments) from
the circulation may undergo evaluation (bearing in
mind the key protective functions these molecules also
perform in innate immunity).
TRANSPLANTATION
Histologic recurrence of DDD after renal transplanta-
tion was ﬁrst reported by Galle et al139 and is
common.140 Histologic recurrence of C3GN probably
also was described in older studies,141 with recent
reports21,42 including cases of CFHR5 nephropathy142
and the CFHR3/1 hybrid gene (in which the related
donor also later developed C3 glomerulopathy).91 A
US retrospective cohort of almost 8,000 pediatric
transplant recipients, including 75 children withDDD, assessed the impact of histologic recurrence of
DDD on graft survival.6 At 5 years, 50% of pediatric
DDD recipients had viable grafts (comparable with the
45% rate identiﬁed in an accompanying literature
review of 78 pediatric and adult DDD recipients). This
was signiﬁcantly lower than the pediatric graft survival
rate of 74% in all-cause ESKD and 72% in non-DDD
forms of GN. Of 29 graft failures in DDD recipients
during the study period, 11 were attributed to recurrent
disease (9 after deceased donor transplantation). How-
ever, the contribution of recurrent disease to the overall
increase in pediatric graft failure rates in DDD recip-
ients was not assessed, except in a subgroup of 29 of
the DDD recipients. Here, 4 graft losses resulting from
biopsy-proven recurrent disease represented a non-
signiﬁcant reduction in median graft survival. Of note,
crescents were seen on graft biopsy only in those with
evidence of DDD recurrence, and were signiﬁcantly
associated with reduced graft survival. Biopsy-proven
recurrence was always accompanied by heavy protei-
nuria, but no clinical or laboratory variables predicted
either DDD recurrence or graft loss. The investigators
concluded that there was no correlation between the
isolated recurrence of dense deposits and reduced graft
survival.6
More recent studies include an Irish cohort of 33
patients with primary idiopathic MPGN in whom graft
failure rates were reported only for those with biopsy-
proven recurrence.30 This included 11 of a total of 18
transplants performed in recipients with (nonfamilial)
DDD. The investigators concluded that 14 grafts lost to
recurrent MPGN at a median of 7.5 years was likely to
represent a reduction in graft half-life.30 In the US
questionnaire-based DDD study comprising 22 mostly
pediatric transplant recipients, 10 grafts were lost
within the ﬁrst 5 years (7 were attributed to recurrent
disease).37 In one C3GN cohort, post-transplant recur-
rence in two individuals was heralded by increased
creatinine levels, subnephrotic proteinuria, and low
serum C3 levels.42 In CFHR nephropathy, 10 patients
(mostly males) have been reported with successful
transplantation (including a recipient whose female
related donor was an asymptomatic carrier of the
mutation), despite histologic recurrence in all three
patients who underwent a biopsy.90,142
CONCLUSIONS
DDD is distinguished histologically from other forms
of C3 glomerulopathy by the presence of osmiophilic,
intramembranous, ribbon-like deposits. Certain clinical
features, including a young age at diagnosis and (in
rare cases) an association with ocular drusen, are more
typical of DDD than other forms of C3 glomerulop-
athy. A diagnosis of DDD does not appear to confer a
worse renal prognosis compared with other forms of
DDD and C3 glomerulopathy 503C3 glomerulopathy. Evidence for the role of AP
dysregulation in C3 glomerulopathy is drawn from
linkage studies in a small number of pedigrees, cohort
studies showing an association with C3NeFs and
complement regulatory gene variants, and animal
models. Recently, linkage was shown for copy number
variation across different CFHR genes in familial C3
glomerulopathy, and a new pathophysiologic concept
of Cfh deregulation has been proposed. Because
progression to ESKD and post-transplant recurrence
is common in all forms of C3 glomerulopathy, thera-
pies that target underlying disease mechanisms are
urgently required.REFERENCES
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